{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:21:53Z","timestamp":1784042513461,"version":"3.55.0"},"reference-count":87,"publisher":"LLC Obyedinennaya Redaktsiya","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ter. arkh."],"published-print":{"date-parts":[[2016]]},"DOI":"10.17116\/terarkh2016888101-108","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T15:37:45Z","timestamp":1460648265000},"page":"101","source":"Crossref","is-referenced-by-count":10,"title":["Aspects of pathogenetic pharmacotherapy for portal hypertension in liver cirrhosis"],"prefix":"10.26442","volume":"88","author":[{"given":"D. V.","family":"Garbuzenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18344","reference":[{"key":"key-10.17116\/terarkh2016888101-108-1","unstructured":"Garbuzenko D.V. Morfofunktsional'naya perestroika pechenochnogo sosudistogo rusla v patogeneze portal'noi gipertenzii pri tsirroze pecheni. Terapevticheskii arkhiv. 2014; 86(2):90-95."},{"key":"key-10.17116\/terarkh2016888101-108-2","unstructured":"Garbuzenko D.V. Mekhanizmy adaptatsii sosudistogo rusla k gemodinamicheskim narusheniyam pri portal'noi gipertenzii. VestnikRAMN. 2013;1:52-57."},{"key":"key-10.17116\/terarkh2016888101-108-3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2013.12.003"},{"key":"key-10.17116\/terarkh2016888101-108-4","doi-asserted-by":"crossref","unstructured":"M\u00f8ller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver. 2000;20(1):51-59.","DOI":"10.1034\/j.1600-0676.2000.020001051.x"},{"key":"key-10.17116\/terarkh2016888101-108-5","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12195"},{"key":"key-10.17116\/terarkh2016888101-108-6","doi-asserted-by":"crossref","unstructured":"Augustin S, Gonzalez A, Genesca J. Acute esophageal variceal bleeding: Current strategies and new perspectives. World J Hepatol. 2010;2(7):261-274.","DOI":"10.4254\/wjh.v2.i7.261"},{"key":"key-10.17116\/terarkh2016888101-108-7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i36.4978"},{"key":"key-10.17116\/terarkh2016888101-108-8","doi-asserted-by":"crossref","unstructured":"Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology. 2006;43(3):385-394.","DOI":"10.1002\/hep.21094"},{"key":"key-10.17116\/terarkh2016888101-108-9","doi-asserted-by":"crossref","unstructured":"Reynaert H, Geerts A. Pharmacological rationale for the use of somatostatin and analogues in portal hypertension. Aliment Pharmacol Ther. 2003;18(4):375-386.","DOI":"10.1046\/j.1365-2036.2003.01657.x"},{"key":"key-10.17116\/terarkh2016888101-108-10","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2013.1385"},{"key":"key-10.17116\/terarkh2016888101-108-11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00218.x"},{"key":"key-10.17116\/terarkh2016888101-108-12","doi-asserted-by":"crossref","unstructured":"Escorsell A, Bandi JC, Andreu V, Moitinho E, Garc\u00eda-Pag\u00e1n JC, Bosch J, Rod\u00e9s J. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology. 2001;120(1):161-169.","DOI":"10.1053\/gast.2001.20892"},{"key":"key-10.17116\/terarkh2016888101-108-13","doi-asserted-by":"crossref","unstructured":"Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010;362(9):823-832.","DOI":"10.1056\/NEJMra0901512"},{"key":"key-10.17116\/terarkh2016888101-108-14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.06.004"},{"key":"key-10.17116\/terarkh2016888101-108-15","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12360"},{"key":"key-10.17116\/terarkh2016888101-108-16","doi-asserted-by":"crossref","unstructured":"Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol. 2008;48(Suppl 1):68-92.","DOI":"10.1016\/j.jhep.2008.01.021"},{"key":"key-10.17116\/terarkh2016888101-108-17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.038"},{"key":"key-10.17116\/terarkh2016888101-108-18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.09.016"},{"key":"key-10.17116\/terarkh2016888101-108-19","doi-asserted-by":"crossref","unstructured":"D\u2019Amico G. The role of vasoactive drugs in the treatment of oesophageal varices. Expert Opin Pharmacother. 2004;5(2):349-360.","DOI":"10.1517\/14656566.5.2.349"},{"key":"key-10.17116\/terarkh2016888101-108-20","doi-asserted-by":"crossref","unstructured":"Bellis L, Berzigotti A, Abraldes JG, Moitinho E, Garc\u00eda-Pag\u00e1n JC, Bosch J, Rod\u00e9s J. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology. 2003;37(2):378-384.","DOI":"10.1053\/jhep.2003.50053"},{"key":"key-10.17116\/terarkh2016888101-108-21","doi-asserted-by":"crossref","unstructured":"Kravetz D. Prevention of recurrent esophageal variceal hemorrhage: review and current recommendations. J Clin Gastroenterol. 2007;41(Suppl 3):318-322.","DOI":"10.1097\/MCG.0b013e318157f0a7"},{"key":"key-10.17116\/terarkh2016888101-108-22","doi-asserted-by":"crossref","unstructured":"Albillos A, Lled\u00f3 JL, Rossi I, P\u00e9rez-P\u00e1ramo M, Tabuenca MJ, Ba\u00f1ares\u00a0R, Iborra J, Garrido A, Escart\u00edn P, Bosch J. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology. 1995;109(4):1257-1265.","DOI":"10.1016\/0016-5085(95)90586-3"},{"key":"key-10.17116\/terarkh2016888101-108-23","doi-asserted-by":"crossref","unstructured":"Ba\u00f1ares R, Moitinho E, Piqueras B, Casado M, Garc\u00eda-Pag\u00e1n JC, de Diego A, Bosch J. Carvedilol, a new nonselective \u03b2-blocker with intrinsic anti-\u03b1-adrenergic activity, has greater portal hypertensive effect than propranolol in patients with cirrhosis. Hepatology. 1999;30(1):79-83.","DOI":"10.1002\/hep.510300124"},{"key":"key-10.17116\/terarkh2016888101-108-24","doi-asserted-by":"crossref","unstructured":"Lo G.H, Chen WC, Wang HM, Yu HC. Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. J Gastroenterol Hepatol. 2012;27(11):1681-1687.","DOI":"10.1111\/j.1440-1746.2012.07244.x"},{"key":"key-10.17116\/terarkh2016888101-108-25","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12634"},{"key":"key-10.17116\/terarkh2016888101-108-26","unstructured":"Garbuzenko D.V., Mikurov A.A. Rol' endotoksemii v razvitii krovotechenii iz varikozno-rasshirennykh ven pishchevoda u bol'nykh tsirrozom pecheni. Rossiiskii meditsinskii zhurnal 2011;6:47-49."},{"key":"key-10.17116\/terarkh2016888101-108-27","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i7.1790"},{"key":"key-10.17116\/terarkh2016888101-108-28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04746.x"},{"key":"key-10.17116\/terarkh2016888101-108-29","doi-asserted-by":"crossref","unstructured":"Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol. 2011;4(6):391-417.","DOI":"10.1177\/1756283X11413002"},{"key":"key-10.17116\/terarkh2016888101-108-30","doi-asserted-by":"crossref","unstructured":"Copple BL, Bai S, Burgoon LD, Moon JO. Hypoxia-inducible factor-1\u03b1 regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int. 2011;31(2):230-244.","DOI":"10.1111\/j.1478-3231.2010.02347.x"},{"key":"key-10.17116\/terarkh2016888101-108-31","unstructured":"Pozzi M, Pizzala DP, Maldini FF, Doretti A, Ratti L. Portal pressure reduction after entecavir treatment in compensated HBV cirrhosis. Hepatogastroenterology. 2009;56(89):231-235."},{"key":"key-10.17116\/terarkh2016888101-108-32","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00162.2009"},{"key":"key-10.17116\/terarkh2016888101-108-33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.03.013"},{"key":"key-10.17116\/terarkh2016888101-108-34","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12025"},{"key":"key-10.17116\/terarkh2016888101-108-35","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i11.1707"},{"key":"key-10.17116\/terarkh2016888101-108-36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26127"},{"key":"key-10.17116\/terarkh2016888101-108-37","doi-asserted-by":"crossref","unstructured":"Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, Nevens F, Sauerbruch T, Heller J. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology. 2007;46(1):242-253.","DOI":"10.1002\/hep.21673"},{"key":"key-10.17116\/terarkh2016888101-108-38","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2012.711851"},{"key":"key-10.17116\/terarkh2016888101-108-39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.043"},{"key":"key-10.17116\/terarkh2016888101-108-40","doi-asserted-by":"publisher","DOI":"10.1042\/cs20090601"},{"key":"key-10.17116\/terarkh2016888101-108-41","unstructured":"Kalambokis GN, Kosta P, Pappas K, Tsianos EV. Haemodynamic and renal effects of tadalafil in patients with cirrhosis. World J Gastroenterol."},{"key":"key-10.17116\/terarkh2016888101-108-42","unstructured":"2010;16(39):5009-5010."},{"key":"key-10.17116\/terarkh2016888101-108-43","doi-asserted-by":"crossref","unstructured":"Fiorucci S, Antonelli E, Morelli A. Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver. Dig Liver Dis. 2003;35(Suppl 2):61-69.","DOI":"10.1016\/S1590-8658(03)00053-7"},{"key":"key-10.17116\/terarkh2016888101-108-44","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.661"},{"key":"key-10.17116\/terarkh2016888101-108-45","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12360"},{"key":"key-10.17116\/terarkh2016888101-108-46","doi-asserted-by":"publisher","DOI":"10.1139\/y10-038"},{"key":"key-10.17116\/terarkh2016888101-108-47","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1157-6"},{"key":"key-10.17116\/terarkh2016888101-108-48","doi-asserted-by":"crossref","unstructured":"Angermayr B, Fernandez M, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J. NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats. Gut. 2007;56(4):560-564.","DOI":"10.1136\/gut.2005.088013"},{"key":"key-10.17116\/terarkh2016888101-108-49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22758"},{"key":"key-10.17116\/terarkh2016888101-108-50","doi-asserted-by":"crossref","unstructured":"D\u2019Amico M., Mejias M., Garcia-Pras E. et al. Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol. 2012;302(10):1191-1198.","DOI":"10.1152\/ajpgi.00252.2011"},{"key":"key-10.17116\/terarkh2016888101-108-51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04896.x"},{"key":"key-10.17116\/terarkh2016888101-108-52","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Guerra M, Garc\u00eda-Pag\u00e1n JC, Turnes J, Bellot P, Deulofeu R, Abraldes JG, Bosch J. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. Hepatology. 2006;43(3):485-491.","DOI":"10.1002\/hep.21080"},{"key":"key-10.17116\/terarkh2016888101-108-53","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.112.040469"},{"key":"key-10.17116\/terarkh2016888101-108-54","doi-asserted-by":"publisher","DOI":"10.1042\/cs20130215"},{"key":"key-10.17116\/terarkh2016888101-108-55","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.06.019"},{"key":"key-10.17116\/terarkh2016888101-108-56","doi-asserted-by":"crossref","unstructured":"Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology. 2006;130(6):1886-1900.","DOI":"10.1053\/j.gastro.2006.01.038"},{"key":"key-10.17116\/terarkh2016888101-108-57","doi-asserted-by":"crossref","unstructured":"Thabut D, Tazi KA, Bonnefont-Rousselot D, Aller M, Farges O, Guimont MC, Tellier Z, Guichard C, Ogier-Denis E, Poynard T, Moreau R, Lebrec D. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. Hepatology. 2007;46(6):1893-1906.","DOI":"10.1002\/hep.21875"},{"key":"key-10.17116\/terarkh2016888101-108-58","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23918"},{"key":"key-10.17116\/terarkh2016888101-108-59","unstructured":"Garbuzenko D.V., Mikurov A.A., Smirnov D.M. Bakterial'naya endotoksinemiya i risk razvitiya krovotechenii iz varikozno-rasshirennykh ven pishchevoda u bol'nykh tsirrozom pecheni. Klinicheskayameditsina 2012;7:48-51."},{"key":"key-10.17116\/terarkh2016888101-108-60","doi-asserted-by":"crossref","unstructured":"Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med. 2003;139(3):186-193.","DOI":"10.7326\/0003-4819-139-3-200308050-00008"},{"key":"key-10.17116\/terarkh2016888101-108-61","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, Vila C, Pardo A, Quintero E, Vargas V, Such J, Gin\u00e8s P, Arroyo V. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133(3):818-824.","DOI":"10.1053\/j.gastro.2007.06.065"},{"key":"key-10.17116\/terarkh2016888101-108-62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.03958.x"},{"key":"key-10.17116\/terarkh2016888101-108-63","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12070"},{"key":"key-10.17116\/terarkh2016888101-108-64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.11.013"},{"key":"key-10.17116\/terarkh2016888101-108-65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097458. ecollection 2014"},{"key":"key-10.17116\/terarkh2016888101-108-66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02020.x"},{"key":"key-10.17116\/terarkh2016888101-108-67","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12280"},{"key":"key-10.17116\/terarkh2016888101-108-68","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12172"},{"key":"key-10.17116\/terarkh2016888101-108-69","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i36.6069"},{"key":"key-10.17116\/terarkh2016888101-108-70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.12.012"},{"key":"key-10.17116\/terarkh2016888101-108-71","doi-asserted-by":"publisher","DOI":"10.1042\/cs20080075"},{"key":"key-10.17116\/terarkh2016888101-108-72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.008"},{"key":"key-10.17116\/terarkh2016888101-108-73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcma.2012.07.001"},{"key":"key-10.17116\/terarkh2016888101-108-74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034230"},{"key":"key-10.17116\/terarkh2016888101-108-75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069309"},{"key":"key-10.17116\/terarkh2016888101-108-76","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26520"},{"key":"key-10.17116\/terarkh2016888101-108-77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083908. ecollection 2014"},{"key":"key-10.17116\/terarkh2016888101-108-78","doi-asserted-by":"crossref","unstructured":"Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery\u00a0J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology. 2007;132(2):709-719.","DOI":"10.1053\/j.gastro.2006.12.041"},{"key":"key-10.17116\/terarkh2016888101-108-79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02651.x"},{"key":"key-10.17116\/terarkh2016888101-108-80","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00477.x"},{"key":"key-10.17116\/terarkh2016888101-108-81","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26939"},{"key":"key-10.17116\/terarkh2016888101-108-82","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23596"},{"key":"key-10.17116\/terarkh2016888101-108-83","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2012.113"},{"key":"key-10.17116\/terarkh2016888101-108-84","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26627"},{"key":"key-10.17116\/terarkh2016888101-108-85","doi-asserted-by":"crossref","unstructured":"Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology. 2007;46(4):1208-1217.","DOI":"10.1002\/hep.21785"},{"key":"key-10.17116\/terarkh2016888101-108-86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.01.025"},{"key":"key-10.17116\/terarkh2016888101-108-87","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12480"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T21:24:46Z","timestamp":1593379486000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/terapevticheskij-arkhiv\/2016\/2\/downloads\/ru\/320040-366020150218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"alternative-id":["terarkh2016888101-108"],"URL":"https:\/\/doi.org\/10.17116\/terarkh2016888101-108","relation":{},"ISSN":["0040-3660"],"issn-type":[{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}